Keyera 1.22B KAPS Buy|Analysts Say Buy at 65, Insiders Priced It at 53

The $1.22 Billion Bet on Canada's NGL Backbone

Keyera Corp. closed its acquisition of the remaining 50% of the KAPS Pipeline on June 17 for C$1.215 billion, becoming the sole owner of a natural gas liquids system that connects Montney and Duvernay production to downstream Alberta markets. The deal was struck — and closed — on the same day, with no public tender process and no competing bid disclosed. That speed signals Keyera was not paying a discovery price; Stonepeak, the infrastructure fund on the other side, agreed to sell at an implied multiple of approximately 11 times 2029 EBITDA based on currently contracted volumes. Eleven times 2029 earnings is not a 2026 price — it is a price anchored to a cash flow profile that does not fully exist yet. Zone 4, the final construction phase, remains on track for a mid-2027 in-service date with ramp-up extending through 2030. The accretion case Keyera management describes as "low-single digit" on distributable cash flow per share sits beyond a four-year horizon. What Keyera bought is strategic control over 120,000 barrels per day of committed volumes across four pipeline zones, with contracts averaging 12 remaining years and 75% take-or-pay protection. The asset itself is not in dispute. The question the deal immediately raises is what price Keyera paid to secure it — and whether the capital structure assembled to fund it treats existing shareholders fairly.

C$1.6 Billion Raised at C$53.55 — While Analysts Say Buy at C$65

Within hours of closing the KAPS acquisition, Keyera launched a C$525 million bought-deal equity offering at C$53.55 per share, led by RBC Capital Markets and TD Securities. By June 22, the company had closed C$604 million in equity — over-allotment exercised in full — and C$1.0 billion in senior unsecured notes, bringing total new capital to C$1.6 billion. The equity was priced at C$53.55. The same week, BMO Capital, CIBC, Scotiabank, and Jefferies each maintained or initiated buy-equivalent ratings with targets of C$60 to C$65. RBC, Keyera's own financial advisor on the acquisition and joint bookrunner on the equity offering, held an Outperform rating with a C$62 target while pricing the bought deal at C$53.55. That gap — 10% to 17% below where the street says the stock should trade — is not unusual in bought deals, which typically price at a discount to attract immediate institutional demand. But it resets the cost basis for every new shareholder who participated at C$53.55 and anchors the near-term dilution against the long-dated accretion. Keyera issued 11.27 million new common shares, expanding its share count at a price the analysts covering it say is below fair value. The hidden assumption in the analyst consensus is that the market will re-rate KEY back to C$60–C$65 as the accretion materializes. What the bought deal reveals is that the institutions actually writing the cheques — including the banks with buy ratings — saw C$53.55 as the clearing price, not C$60. Whether those two views are compatible or contradictory is the question the next 12 months will answer.

The Verification Window: Zone 4, Net Debt, and the 2029 Accretion Clock

The entire investment case for Keyera post-KAPS rests on a sequence of execution milestones that are concrete, dated, and measurable. Zone 4 in-service is targeted for mid-2027, with volume ramp through 2030. Net debt to adjusted EBITDA is expected to land within the company's 2.5x to 3.0x target range by 2028 — Keyera committed an additional C$100 million in 2026 growth capital beyond its prior C$550–C$625 million guidance to fund its increased Zone 4 share. The senior notes issued to part-fund the deal carry coupon rates of 3.942% due 2031 and 4.638% due 2036, replacing Keyera Partnership's existing 3.96% notes due October 2026 — a refinancing that extends duration but marginally increases the blended cost. The EBITDA per share CAGR guidance has been revised upward to 16%–18% through 2027, from 15%–17% previously, and the 7%–8% CAGR from 2027 to 2029 is unchanged. Three variables most sharply discriminate whether the C$53.55 equity price and C$60+ analyst targets converge: first, Zone 4 coming in on time and on budget; second, contracted volumes holding at or above current commitments through the ramp period; third, net debt staying within 2.5x–3.0x as growth capital is deployed. If Zone 4 slips, the 2029 accretion multiple expands beyond 11x and the equity-raise discount becomes permanently dilutive rather than temporarily so. If volumes hold and Zone 4 delivers on schedule, the distributable cash flow per share inflection point arrives in 2028–2029 and the current share count, though larger, catches the full benefit of a fully contracted, low-maintenance-capital system. A holder bought before the equity raise faces the question of whether to average down at C$53.55 or hold at a higher cost basis through the execution window. A watcher on the sidelines sees a stock priced below analyst consensus by the banks that just underwrote the deal — and must decide whether that discount represents an entry, or whether Zone 4 and leverage risk make the next 18 months the wrong time to step in. The confirmation variable is not an analyst target — it is the mid-2027 Zone 4 in-service announcement and the first distributable cash flow per share figure that follows it.